NEW YORK, Feb 1, 2026 - (ACN Newswire via SeaPRwire.com) - TCG.Zone (The Collectors Grid), a key player in the global collectibles infrastructure and ecosystem, has officially unveiled its strategic shift toward prioritizing investments in high-value, rare collectible assets. This strategic realignment underscores the company’s commitment to tapping into the long-term value and cultural significance of elite collectibles, with the recent participation in a high-profile international auction serving as a pivotal first step in this new direction.Recently, the world's only Pokémon card graded PSA 10 - Pikachu Illustrator - once again became a focal point of global attention across the collectibles and cultural landscape. As a long-term contributor to TCG infrastructure and the broader collectibles ecosystem, The Collectors Grid(TCG.Zone) participated in and witnessed this historically significant moment.Recognized as one of the most iconic works in Pokémon card history, Pikachu Illustrator is distinguished not only by its extreme rarity, but also by its symbolic representation of Pokémon culture, artistic value, and generational memory.The Legendary Status of the World's Only PSA 10According to publicly available information, the world's only PSA 10 "Pikachu Illustrator" card is currently owned by Logan Paul. The card was involved in a high-profile transaction in 2022, valued at nearly USD 5.3 million, marking a defining milestone in the history of Pokémon card collecting.The Industry Significance of Goldin AuctionsAlthough Logan Paul's acquisition of the card did not take place through Goldin, the Goldin auction platform has continued to play an important role in the card's contemporary circulation and visibility. As one of the world's most influential high-end collectibles auction platforms, Goldin's auction framework and the attention it generates brought renewed global focus to this legendary card, further positioning Pokémon cards within the broader mainstream collectibles market.Netflix Documentary Captures a Cultural MomentAmid the phenomenon-level attention generated by this card on the Goldin platform, Netflix documented the full auction process and produced a dedicated documentary. Approached from a cultural and historical perspective, the documentary highlights the unique position of Pikachu Illustrator within the modern collectibles ecosystem, elevating it beyond price alone and framing it as a lasting cultural reference.Global Participation and TCG.Zone's InvolvementThe discussions and auction activity surrounding Pikachu Illustrator attracted participation from top collectors, institutions, and professional teams from around the world. TCG.Zone was among the active participants in the bidding process. During the auction, TCG.Zone submitted a bid of USD 5,000,000. Although the bid was ultimately surpassed by a higher offer, TCG.Zone remained deeply engaged throughout the process and witnessed this pivotal moment firsthand.Continuing to Follow the Card's Future TrajectoryIn post-auction interviews, TCG.Zone stated that this participation does not mark an endpoint. The team will continue to closely monitor the movement and future trajectory of the world's only PSA 10 Pikachu Illustrator, and does not rule out participating again should the right opportunity arise. This event represents more than an auction. It stands as a collective reflection on rarity, cultural identity, and long-term value.The story of Pikachu Illustrator continues to unfold,and remains an enduring chapter in the global history of Pokémon card collecting.About TCGThe Collectors Grid is an on-chain infrastructure designed to formalize collectibles as a structured asset class. By integrating provenance, ownership, pricing, and settlement at the protocol level, it addresses long-standing inefficiencies in the global collectibles market. The platform enables institutional-grade transparency while preserving the unique characteristics of collectible assets. Positioned as a settlement layer rather than a marketplace, The Collectors Grid provides the foundational rails for liquidity, valuation, and long-term capital participation in cards, IP, and high-value collectibles.Social LinksTwitter: https://x.com/tcgzoneofficialInstagram: https://www.instagram.com/tcgzoneofficial/Telegram: https://t.me/tcgzoneofficialMedia ContactBrand : The Collectors Grid (tcg.zone)Contact: AnnieWebsite: https://www.tcg.zone Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
MOSCOW, Jan 31, 2026 - (ACN Newswire via SeaPRwire.com) - Expert Dialogues were held for the first time within the Open Dialogue framework at the Russia National Centre in Moscow on 30 January. The forum focused on five major megatrends shaping global economic, technological, and social development, bringing together international experts to explore how these forces will influence societies and industries in the decades ahead.Organized by the Russia National Centre in partnership with the Centre for Cross-Industry Expertise "The Third Rome" and supported by the Presidential Executive Office, the forum brought together experts from around the world to discuss economic, technological, and social transformations.Maksim Oreshkin, Deputy Head of the Russian Executive Administration for Global Trends, presented five key megatrends that, he said, are already shaping global development and will continue to influence the world in the coming decades."By 2026, Open Dialogue has become an international platform uniting experts from across the world to discuss the future of the planet, the global economy, and society," Oreshkin said. "Understanding these processes is essential for preparing for change and leveraging it in the interests of nations and, above all, people. Today, I will focus on five key megatrends — while not treating artificial intelligence as a separate trend, because it has already become an integral part of our lives."1. A New Global Economic Paradigm: Globalisation 2.0A shift from traditional globalisation to a more decentralised system was described. BRICS+ countries now play a growing role in the global economy, technological development, and demographic trends, while the Global South is increasingly engaging in direct trade and national-currency settlements."Globalisation hasn't ended; it has changed," Oreshkin said. "Sovereignty — at state, social, and economic levels — is now the key to competitiveness. Only countries that preserve all three levels can lead in a multipolar world."China, the USA, India, and Russia are identified as major global powers, while highlighting emerging growth centres such as Indonesia and "connector countries" like the United Arab Emirates. Digital platforms and decentralised networks are also becoming independent participants in the world economy.2. Platformisation and Institutional AutomationThe second megatrend highlights the rise of platforms and automation across all sectors. Platforms and algorithms are increasingly shaping decision-making in healthcare, education, finance, trade, and beyond."Platform solutions enhance efficiency and reduce transaction costs through self-adjusting algorithms," Oreshkin said. "Countries without technological sovereignty risk becoming dependent on external platforms, which can have strategic consequences during conflicts."3. Transformation of the Global Financial SystemIt was noted that traditional financial models face mounting challenges, including rising public debt, widening inequality, and geopolitical fragmentation. Technologies such as blockchain, artificial intelligence, and digital platforms are creating alternative financial mechanisms, including decentralised finance."The traditional model of cross-border payments is under pressure. Decentralised systems and digital technologies are reshaping the financial system," he said.4. Demographic Shifts and ChallengesThe fourth megatrend concerns global population dynamics. Global fertility rates have fallen sharply, with some countries facing critical declines. By the end of the 21st century, the working-age population may shrink significantly, while the proportion of elderly people rises, placing pressure on pension systems and social services."Even in Africa, the ratio of elderly to working-age population will rise to 30%, and globally to 56%," Oreshkin explained. "Education demand will decrease, but healthcare and social service needs will grow. These interconnected trends will amplify each other."5. Human Capital Development in the Technological EraThe final megatrend focuses on human capital in a rapidly changing technological environment.Autonomous systems, digital platforms, and artificial intelligence are transforming education, work, and healthcare, while biotechnologies expand human capabilities."AI is both a challenge and an opportunity," Oreshkin said. "It allows personalized learning paths and supports teachers.Professions are changing: mid-level specialists will be in demand, and companies must retrain employees from junior positions. The social sphere will also evolve, ensuring active longevity in the new demographic era."Global PerspectiveThroughout the presentation, Oreshkin illustrated each trend with real-life examples from different continents: a manager from Asia, a farmer from Africa, and a homemaker from Eastern Europe. He highlighted that innovations in Africa could improve education and healthcare, Eastern Europe may see rising living standards and more efficient social systems, and Asia will require reskilling to meet changing labor demands."The world has entered a period of significant change in finance, demography, and other spheres. States, companies, and individuals must be prepared. Those who understand and adapt will shape the future," Oreshkin concluded.Open Dialogue on AirThis year, Open Dialogue introduced a podcast format — Open Dialogue on Air — featuring global experts discussing key trends in international development. Participants include award-winning Chinese sci-fi writer Chen Qiufan, Dr. Selina Neri of the Future Readiness Academy, Dr. Rais Hussin of EMIR Research (Malaysia), Prof. Wang Feng of UC Irvine, and global strategist Dr. Parag Khanna.First held in April 2025 at the Russia National Centre, the Open Dialogue brought together over 3,000 experts from dozens of countries. By presidential decree, it will now be held annually.Social LinksTelegram: https://t.me/gowithrussiaVK: https://vk.com/gowithrussiaOK: https://ok.ru/gowithrussiaDZen: https://dzen.ru/gowithrussiaContact for the mediaBrand: Russia National CentreContact: Media teamEmail: Pressa@russia.ru Website: https://russia.ruEssay Submission: https://dialog.russia.ru/en/ Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
SHENZHEN, Jan 30, 2026 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement published by the Group on 22 April 2025 for details) received approval from the National Medical Products Administration of China (NMPA) on 30 January 2026 for the New Drug Application (NDA) of ruxolitinib phosphate cream (the “Product”) for the treatment of non-segmental vitiligo with facial involvement in children aged 12 years and older and adult patients. It is the first and only targeted drug approved in China for vitiligo, addressing a significant unmet clinical need.Ruxolitinib phosphate cream is the first and only drug approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for repigmentation in nonsegmental vitiligo[1,2]. Prior to receiving formal NDA approval, the Group benefited from the “Early and Pilot Implementation” policy granted to the Hainan Free Trade Port and Lecheng Pilot Zone (“Lecheng Pilot Zone”), the “Hong Kong and Macau Medicine and Equipment Connect” policy, and the clinically urgently needed imported drug policies of the Beijing and Tianjin Free Trade Zones, and had already initiated the pilot application of ruxolitinib phosphate cream. Currently, Boao Super Hospital has prescribed ruxolitinib phosphate cream to over 7,000 patients with non-segmental vitiligo, and more than twenty hospitals in Guangzhou, Shenzhen, Dongguan, Foshan, Zhongshan, Zhuhai, Jiangmen, Huizhou, Beijing and Tianjin have provided prescription services for the Product, demonstrating its clinical potential.The product has shown positive results in both overseas clinical studies and the real-world study in China: in two identical Phase III double-blind, randomized, placebo-controlled studies (TRuE-V1 and TRuE-V2) conducted overseas, the proportion of patients achieving the primary efficacy endpoint of at least 75% improvement in the Facial Vitiligo Area Score Index (F-VASI 75) after 24 weeks of treatment with ruxolitinib phosphate cream was 29.9% in both studies, significantly higher than the 7.5% and 12.9% in the placebo groups, respectively. Continued use up to 52 weeks showed sustained repigmentation[3]. In accordance with the relevant regulations of the Lecheng Pilot Zone's real-world data application pilot project, ruxolitinib phosphate cream underwent real-world study in China, demonstrating positive efficacy consistent with the results of overseas pivotal clinical studies. All secondary efficacy endpoints in both domestic and overseas clinical studies showed a benefit trend consistent with the primary efficacy endpoint, and the treatment effect for vitiligo continued to improve with prolonged treatment. Furthermore, according to safety monitoring data from the Lecheng Pilot Zone, no new safety event was identified, no adverse event (AE) leading to discontinuation or withdrawal of treatment occurred, and no study drug-related serious adverse event (SAE) occurred.This approval in vitiligo brings new hope for treatment to over 10 million vitiligo patients in China, addressing urgent clinical needs. At the same time, it will add to Dermavon’s product portfolio in the field of skin treatment, potentially synergizing with Dermavon’s commercialized innovative drug ILUMETRI (tildrakizumab injection), commercialized exclusive drug Hirudoid (mucopolysaccharide polysulfate cream), and a series of innovative drugs under development and dermatological skin care products, in terms of expert network and market resources, thereby potentially enhancing Dermavon's position in the field of skin health.Furthermore, the Phase III clinical trial in China of ruxolitinib phosphate cream for the treatment of mild to moderate atopic dermatitis (AD) has achieved positive results. Currently, the Group is actively advancing the NDA for ruxolitinib phosphate cream for the treatment of AD in China, which, if approved, will provide a new treatment option for a broader patient population with AD in China.About VitiligoVitiligo is a chronic autoimmune disease characterized by depigmentation of the skin, which results from the loss of pigment-producing cells known as melanocytes. It is estimated that there are approximately 10.3 million vitiligo patients in China and non-segmental vitiligo patients account for approximately 8.2 million[4]. Existing therapies, such as topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs), have clinical limitations, with adverse reactions or limited efficacy with long-term use. The NDA approval of ruxolitinib phosphate cream successfully fills the gap in targeted drug treatment for vitiligo and is of great landmark significance.More About Ruxolitinib Phosphate CreamRuxolitinib phosphate cream (Opzelura®), a novel cream formulation of the selective JAK1/JAK2 inhibitor ruxolitinib developed by Incyte, is approved for the topical treatment of nonsegmental vitiligo in adult and patients aged 12 years and older, and for the short-term and non-continuous chronic treatment of mild to moderate AD in patients aged 2 years and older without immunodeficiency in the U.S. In Europe, ruxolitinib phosphate cream is approved for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.The Group, through a subsidiary of Dermavon entered into a Collaboration and License Agreement with Incyte for ruxolitinib phosphate cream on 2 December 2022, obtaining an exclusive license to develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights for the Product outside Mainland China to the Group (excluding Dermavon and its subsidiary).Incyte has worldwide rights for the development and commercialization of ruxolitinib phosphate cream, marketed in the United States and Europe as Opzelura®. Opzelura® and the Opzelura® logo are registered trademarks of Incyte.About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.Reference:1. The U.S. FDA approval information can be found on the Incyte official website, as follows:https://investor.incyte.com/news-releases/news-release-details/incyte-announces-us-fda-approval-opzeluratm-ruxolitinib-cream2. The EMA approval information can be found on the Incyte official website, as follows:https://investor.incyte.com/news-releases/news-release-details/incyte-announces-european-commission-approval-opzelurar3. The clinical studies information can be found on the Opzelura® official website, as follows:https://www.opzelura.com/opzelura-prescribing-information4. China Insights Consultancy’s industrial reportCMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/ Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
OSAKA, Japan, January 30, 2026 - (ACN Newswire via SeaPRwire.com) - SuperX AI Technology Limited (NASDAQ: SUPX) ("the Company" or "SuperX"), an emerging AI Data Center infrastructure solutions provider, today announced the official start of production at its newly established SuperX Global Supply Center in Japan. Located in Tsu City, Mie Prefecture, Japan, this facility represents SuperX’s primary supply hub. The commencement of production at this facility marks the Company's transition from engineering and preparation to scaled commercial production. Located in Japan, this center is established to serve SuperX’s global customer base.Strategic Rationale & Operational FocusSuperX selected Japan for its first supply center to integrate Japan’s established industrial capabilities with SuperX’s technical expertise. The center focuses on three pragmatic objectives:Manufacturing Quality: Leveraging Japan’s rigorous execution standards to ensure high reliability for high-performance AI servers.Production Scale: The facility is currently capable of delivering up to 20,000 AI servers annually, providing the capacity needed to fulfill immediate demand, and expandable to fulfil future global orders.Global Export: Serving as a consolidated hub for system integration and logistics, streamlining delivery to international markets.Market ProgressThe commencement of production at the SuperX Global Supply Center supports the Company’s immediate commercial execution. In January, 2026, SuperX has secured customer purchase orders with an estimated total value of USD 910 million. Separately, the Company has also entered into MOUs with several potential customers for the purchase of 5,000 units of AI servers within the next 12 months, with an estimated total order value of up to USD 2.1 billion.Globalized Support ServicesTo better support customers through AI server product deployment and post-sales services, SuperX is rolling out a standardized technical service system, including 24/7 response via a global support center based in Singapore, expert-level technical support, and end-to-end services. For domestic Japanese delivery and operations, SuperX combines a global technical team with a local spare-parts network. This enables customizable project implementation services, and tiered SLA-backed on-site maintenance options to support rapid go-live and stable operation. Executive Commentary"This is a foundational moment for SuperX," said Dr. Chenhong Huang, Chairman and CEO of SuperX. "By establishing our first SuperX Global Supply Center in Japan, we are securing the engineering discipline and quality assurance required to compete on a global stage. This facility allows us to control our production standards and deliver reliable, full-stack AI solutions to our customers worldwide."About SuperX AI Technology Limited (NASDAQ: SUPX) SuperX AI Technology Limited is an AI infrastructure solutions provider, offering a comprehensive portfolio of proprietary hardware, advanced software, and end-to-end services for AI data centers. The Company's services include advanced solution design and planning, cost-effective infrastructure product integration, and end-to-end operations and maintenance. Its core products include high-performance AI servers, 800 Volts Direct Current (800VDC) solutions, high-density liquid cooling solutions, as well as AI cloud and AI agents. Headquartered in-Singapore, the Company serves institutional clients globally, including enterprises, research institutions, and cloud and edge computing deployments. For more information, please visit:www.superx.sg Safe Harbor Statement This press release may contain forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The reader is cautioned not to rely on these forward-looking statements. The forward-looking events discussed in this press release, including quantities and estimated value of orders and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. The quantities and estimated order value mentioned in the MOUsA are non-binding and subject to the execution of purchase orders and definitive agreements . Actual delivery schedules and value of AI servers may vary based on customer data center readiness and supply chain conditions. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur. Follow our social media: X.com:https://x.com/SUPERX_AI_ LinkedIn:https://www.linkedin.com/company/superx-ai Facebook:https://www.facebook.com/people/Super-X-AI-Technology-Limited/61578918040072/# Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
HONG KONG, January 30, 2026 - (ACN Newswire via SeaPRwire.com) – As China’s first batch of Level 3 (L3) conditionally autonomous driving vehicles receives official market access, advanced smart driving is poised for its inaugural year of commercial explosion. At this pivotal juncture, Cheche Group Inc. (CCG) ("Cheche" or the "Company"), a leading global InsurTech platform, announced the signing of a strategic cooperation agreement with Volkswagen (Anhui) Digital Sales and Services Co., Ltd. (hereinafter "DSSO") and Beijing Cardif Airstar Property & Casualty Insurance Co., Ltd. (hereinafter "Cardif Airstar Insurance").This tripartite collaboration is more than just a deep dive into high-quality growth for New Energy Vehicle (NEV) insurance; it represents a core transition from "digitization" to "intelligence." The partnership establishes three strategic directions for synergy. First, it focuses on the transformation of product formats by leveraging Cheche’s SaaS platform to co-create an integrated "Insurance + Value-Added Services" package, enabling the efficient, one-stop fulfillment of high-value services. Second, it upgrades pricing capabilities by deeply integrating compliant driving data with dynamic vehicle information, utilizing AI-driven risk profiling to achieve differentiated precision pricing while addressing the complex challenge of liability determination in human-machine co-driving scenarios. Finally, it expands the ecosystem dimension by embedding insurance services throughout the vehicle sales and after-sales process, extending the business from a single policy to a full-lifecycle service ecosystem that encompasses renewal management and mobility protection.01. Smart Driving Insurance: Securing "Pricing Authority" in the L3 Mass Production EraTraditional auto insurance has long struggled with "human-machine co-driving" scenarios due to a lack of real-time dynamic data for liability determination and precise risk identification. Having served leading automakers such as Tesla, Li Auto, and Xiaomi, Cheche provides VW Anhui Digital with an embedded SaaS system centered on data attribution and dynamic pricing.Through this SaaS infrastructure, vehicle driving data is seamlessly synchronized with BNP Paribas Star’s actuarial models. This AI-driven joint risk profiling not only resolves the technical difficulties of liability judgment in smart driving scenarios but also delivers a "low-premium rewards for safe drivers," serving as a vital solution to the profitability challenges currently facing the NEV insurance industry.02. Ecosystem Breakthrough: Leveraging the "Xiaomi + Volkswagen DSSO" New Quality Productive ForcesInvestors are closely watching the cross-sector dynamics underpinning this collaboration. Cardif Airstar Insurance was co-founded by Xiaomi Group, Volkswagen Financial Services, and Cardif Airstar Insurance, combining the strengths of an internet giant, a global financial powerhouse, and a leading smart automaker.As the hub connecting these forces with Volkswagen’s Hefei Intelligent Electric Vehicle Center, Cheche is penetrating the world’s top smart driving supply chains. This is not merely system integration; it marks Cheche’s evolution into a digital operator within the "Vehicle-Battery-Charging-Insurance" integrated landscape. Amid policy tailwinds such as "New Quality Productive Forces," Cheche’s closed-loop ecosystem is becoming a definitive growth pole for insurance and tech capital.03. Scenario Transformation: From Transactional Policies to Full-Lifecycle OperationsIn 2026, as the automotive market shifts from a competition over hardware parameters to a competition over user experience, Cheche is helping DSSO deeply couple insurance services with the car-buying and after-sales journey. The integrated service package transforms insurance from a low-frequency tool into a high-frequency touchpoint for user engagement.Christian Koenig, After-sales Director of DSSO, noted that Cheche’s technical foundation allowed the partnership to advance rapidly from a high starting point. This "plug-and-play" empowerment capability, proven by mainstream automakers, has become a technical moat for Cheche in the capital markets.04. Conclusion: The Final Piece of the Trillion-Dollar Blue OceanThe year 2026 marks the point where NEV insurance evolves from scale expansion to intelligent upgrades. Cheche will continue to advance its AI pricing engine, driving the leap from digital to intelligent services.According to data released by the Ministry of Public Security on January 26, China’s NEV ownership reached 43.97 million units by the end of 2025, accounting for 12.01% of the total vehicle population—a growth rate exceeding 40% year-over-year. In this environment, those who define the insurance standards for the smart driving era will control the entry point to future mobility. With its high barriers to entry via OEM partnerships and forward-looking AI layouts, Cheche is racing toward becoming a leader in the trillion-dollar NEV insurance market. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
HONG KONG, January 30, 2026 - (ACN Newswire via SeaPRwire.com) – 27 January 2026, Nissin Foods (Hong Kong) Charity Fund (“Charity Fund”) announced its continued support for elite athletes from The Education University of Hong Kong (“EdUHK”) for the fourth consecutive year. The Presentation Ceremony for the Nissin Foods Scholarship for Elite Athletes 2025/2026 was held to honour seven outstanding athletes who not only demonstrate excellence in their respective sports but also aspire to become future educators. The scholarship will cover their full tuition fees throughout their entire study period, enabling them to pursue their academic and athletic goals without financial concerns.Established in 2022 by the Nissin Foods (Hong Kong) Charity Fund, the scholarship is designed to encourage elite athletes enrolled in the Bachelor of Health Education (Honours), Bachelor of Science (Honours) in Sports Science and Coaching, or the Postgraduate Diploma in Education programme at EdUHK. The initiative aims to support their dual career development, empowering them to become qualified health educators while continuing to strive for excellence in their athletic performance.The seven awardees for the 2025/2026 academic year include new and renewing recipients. The four new awardees are: Mr. MOK Pak Fan (triathlon), Mr. WONG Pak Yiu (triathlon), Miss HO Kin Yiu (volleyball), and Miss YAN Nuo (shuttlecock). In addition to welcoming new scholars, the Charity Fund also made the scholarship renewable to support the elite athletes throughout their study period. The three recipients of the renewed scholarship are: Mr. CHOI Kwan Lok (cycling, retired), Mr. CHEN Pak Hong (rowing), and Mr. Joseph LAU (cycling).Mr. Kiyotaka ANDO, Chairman of Nissin Foods (Hong Kong) Charity Fund, said, “Having been deeply rooted in Hong Kong for over four decades, Nissin Foods is steadfast in its mission to give back to the community. This scholarship is a direct reflection of our founder Mr. Momofuku Ando’s philosophy that ‘Eating and sports are the two axles of health.’ By supporting these talented athletes at EdUHK for the fourth year, we are not just providing financial support, we are investing in future leaders who will champion health and wellness in our society. We are proud to empower them on their dual career path, confident that they will inspire the next generation as both accomplished athletes and dedicated educators.”Expressing his profound gratitude for the long-standing partnership, Professor Chetwyn CHAN, Vice President (Research and Development) of EdUHK, said, “EdUHK is dedicated to promoting sustainable dual-career pathways for high-performance athletes. The generous Nissin Foods Scholarship for Elite Athletes allows us to support both active and retired athletes in advancing their educational pursuits, while also recognising their exceptional sporting accomplishments. I would like to extend my heartfelt congratulations to all the scholarship recipients, who demonstrated great passion, determination, and a sense of mission, and sincerely thank the Nissin Foods (Hong Kong) Charity Fund, and Mr Ando for the tremendous support and confidence in health education and the development of elite athletes.”Accomplished volleyball player Miss HO Kin Yiu, recipient of the scholarship from the Postgraduate Diploma in Education, majoring in Chinese and Physical Education, shared her heartfelt appreciation to the Charity Fund, “The support of the scholarship empowers us, as elite athlete-students, to chase our aspirations and make a meaningful influence on society. We are confident that we can help create a brighter future through the spirit of sports and education.”PhotoMr. Kiyotaka ANDO, Chairman of Nissin Foods (Hong Kong) Charity Fund (middle right), and Professor Chetwyn CHAN, Vice President (Research and Development) of EdUHK (middle left), attended the Presentation Ceremony for Nissin Foods Scholarship for Elite Athletes 2025/2026 on 27 January 2026. Five scholarship recipients attended the ceremony, including four new awardees for the 2025/2026 academic year, namely: (from left to right) Mr. MOK Pak Fan, Mr. WONG Pak Yiu, Miss HO Kin Yiu, and Miss YAN Nuo, as well as the renewed awardee - Mr. CHOI Kwan Lok. Awardees of the Nissin Foods Scholarship for Elite Athletes 2025/2026 are achieving great success in their individual disciplines. From top left: Mr. WONG Pak Yiu (triathlon), Miss HO Kin Yiu (volleyball), Mr. MOK Pak Fan (triathlon), Miss YAN Nuo (shuttlecock), Mr. CHOI Kwan Lok (cycling, retired), Mr. CHEN Pak Hong (rowing), and Mr. Joseph LAU (cycling).About Nissin Foods (Hong Kong) Charity FundThe Nissin Foods (Hong Kong) Charity Fund (“Charity Fund”) was set up in September 2020 by way of a trust deed by Nissin Foods Company Limited (Stock code: 1475). The objectives of the Charity Fund are: a) to advance education, teaching, learning, arts, science and academic research; b) to make provision for people in need; and c) to carry out works of a charitable nature that are beneficial to the Hong Kong community. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
深圳, 2026年1月30日 - (亚太商讯 via SeaPRwire.com) - 康哲药业控股有限公司 （"康哲药业"）欣然宣布，旗下德镁医药有限公司（"德镁医药"，专业聚焦皮肤健康的创新型医药企业，正申请于香港联合交易所有限公司主板独立上市，详见康哲药业日期为2025年4月22日发布的公告）已于2026年1月30日获得中国国家药品监督管理局（NMPA）批准磷酸芦可替尼乳膏（白癜风适应症）（"产品"）新药上市许可申请（NDA）。产品用于治疗12岁及以上儿童和成人患者伴面部受累的非节段型白癜风，是中国批准的首款且唯一用于白癜风治疗的靶向药，满足巨大未被满足的临床需求。磷酸芦可替尼乳膏是经美国食品和药物管理局（FDA）及欧洲药品管理局（EMA）批准的首款也是唯一一款用于非节段型白癜风复色的药物[1,2]，在产品正式获得NDA批准之前，康哲药业受益于国家赋予海南自由贸易港及乐城先行区（"乐城先行区"）"先行先试"政策、"港澳药械通"政策、北京市及天津自贸试验区的临床急需进口药品政策，已启动磷酸芦可替尼乳膏的试点应用。目前博鳌超级医院已为超7,000名非节段型白癜风患者开具磷酸芦可替尼乳膏处方，且广州、深圳、东莞、佛山、中山、珠海、江门、惠州、北京及天津共二十余家医院已提供该药品处方服务，体现了其临床价值。产品在境外临床研究与中国真实世界研究中均展现出积极结果：其在境外开展的两项相同设计的III期双盲、随机、安慰剂对照研究（TRuE-V1和TRuE-V2）中，产品治疗24周后达到主要疗效指标面部白癜风面积评分指数改善至少75%（F-VASI 75）的患者比例均为29.9%，显著高于安慰剂组的7.5%和12.9%，持续使用至52周，复色效果持续[3]。根据乐城先行区药品真实世界数据应用试点项目有关规定，磷酸芦可替尼乳膏在中国开展真实世界研究，疗效积极，与境外关键临床研究结果一致。境内外临床研究中所有的次要疗效指标均显示出与主要疗效指标一致的获益趋势，且白癜风治疗效果随疗程延长持续改善。同时，根据乐城先行区安全性监测数据，未发现新的安全性事件，未发生导致停药或退出的不良事件（AE），未发生研究药物相关的严重不良事件（SAE）。此次产品白癜风适应症获批，将为国内千万白癜风患者带来治疗新希望，满足市场迫切的临床需求。同时，产品将进一步丰富德镁医药在皮肤治疗领域的产品矩阵，并有望与现有处于商业化阶段的创新药益路取（替瑞奇珠单抗注射液）、独家药喜辽妥（多磺酸粘多糖乳膏），以及系列在研创新药和皮肤学级护肤品等在专家网络与市场资源等方面产生协同，提升德镁医药在皮肤健康领域的地位。此外，康哲药业于中国开展的磷酸芦可替尼乳膏治疗轻中度特应性皮炎患者的III期临床试验，已取得阳性结果。截至目前，康哲药业正在中国积极推进磷酸芦可替尼乳膏治疗特应性皮炎的新药上市申请，如若获批上市，将为中国广大特应性皮炎患者群体提供新的治疗选择。关于白癜风适应症白癜风是一种慢性自身免疫性疾病，其特征是皮肤色素脱失，其发病原因为产生色素的细胞即黑素细胞的缺失。据估算，中国约有1030万人患有白癜风，其中约820万人患有非节段型白癜风[4]。现有疗法，如外用糖皮质激素（TCS）及外用钙调神经磷酸酶抑制剂（TCIs）存在临床缺陷，长期用药有不良反应或疗效有限。磷酸芦可替尼乳膏NDA获批，成功填补了白癜风靶向药物治疗的空白，具有重大标志性意义。关于磷酸芦可替尼乳膏的更多信息磷酸芦可替尼乳膏（Opzelura®）是Incyte开发的选择性JAK1/JAK2抑制剂芦可替尼制成的一种创新型乳膏，在美国获批用于局部治疗成人及12岁及以上患者的非节段型白癜风，及2岁及以上非免疫力功能低下患者的轻度至中度特应性皮炎的局部短期和非连续性慢性治疗。在欧洲，磷酸芦可替尼乳膏被批准用于治疗成年及12岁及以上青少年面部受累的非节段型白癜风。康哲药业于2022年12月2日，通过德镁医药的附属公司与Incyte就磷酸芦可替尼乳膏订立合作和许可协议（"许可协议"），获得在中国大陆、香港特别行政区、澳门特别行政区、台湾地区及东南亚十一囯（"区域"）研发、注册及商业化产品的独家许可权利，以及在区域内生产产品的非独家许可权利。德镁医药的附属公司已将磷酸芦可替尼乳膏除中国大陆外的其他区域的相关权利再许可予康哲药业（不包括德镁医药及其附属公司）。Incyte拥有磷酸芦可替尼乳膏全球开发和商业化权利，在美国及欧洲以Opzelura®的名称销售。Opzelura®和Opzelura®标识是Incyte的注册商标。关于康哲药业康哲药业是一家链接医药创新与商业化，把控产品全生命周期管理的开放式平台型企业，致力于提供有竞争力的产品和服务，满足尚未满足的医疗需求。康哲药业专注于全球首创（FIC）及同类最优（BIC）的创新产品，并高效推进创新产品临床研究开发和商业化进程，赋能科研成果向诊疗实践的持续转化，造福患者。康哲药业聚焦专科领域，拥有被验证的商业化能力，广泛的渠道覆盖和多疾病领域专家资源，核心在售产品已获领先的学术与市场地位。康哲药业围绕优势专科领域不断纵深发展，以巩固心脑血管/消化/眼科/皮肤健康业务竞争力，带来专科规模效率，其中皮肤健康业务（德镁医药）已成为其细分领域的龙头企业，并拟于联交所独立上市。同时，康哲药业持续推动研产销全产业链在东南亚及中东区域运营发展，以获取新兴市场的增量，助力集团实现高质量可持续发展。参考文献/资料1.FDA批准信息可在Incyte官网查询，网址：https://investor.incyte.com/news-releases/news-release-details/incyte-announces-us-fda-approval-opzeluratm-ruxolitinib-cream2.EMA批准信息可在Incyte官网查询，网址：https://investor.incyte.com/news-releases/news-release-details/incyte-announces-european-commission-approval-opzelurar3.相关临床研究信息可在Opzelura®官网查询，网址：https://www.opzelura.com/opzelura-prescribing-information4.数据来自灼识咨询报告康哲药业免责与前瞻性声明本新闻无意向您做任何产品的推广，非广告用途。本新闻不对任何药品和-医疗器械和/或适应症作推荐。若您想了解具体疾病诊疗信息，请遵从医生或其他医疗卫生专业人士的意见或指导。医疗卫生专业人士作出的任何与治疗有关的决定应根据患者的具体情况并遵照药品说明书。由康哲药业编制的此新闻不构成购买或认购任何证券的任何要约或邀请，不形成任何合约或任何其他约束性承诺的依据或加以依赖。本新闻由康哲药业根据其认为可靠之资料及数据编制，但康哲药业并无进行任何说明或保证、明述或暗示，或其他表述，对本新闻内容的真实性、准确性、完整性、公平性及合理性不应加以依赖。本新闻中讨论的若干事宜可能包含涉及康哲药业的市场机会及业务前景的陈述，该等陈述分别或统称为前瞻性声明。该等前瞻性声明并非对未来表现的保证，存在已知及未知的风险、不明朗性及难以预知的假设。康哲药业并不采纳本新闻包含的第三方所做的任何前瞻性声明及预测，康哲药业对该等第三方声明及预测不承担责任。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
PUTNAM, CT AND ROMEOVILLE, IL, Jan 29, 2026 - (ACN Newswire via SeaPRwire.com) - Formerra and GEON® Performance Solutions today announced an agreement that designates Formerra as the preferred distributor of Foster®, LLC medical compounds in Europe. This adds to Formerra's current distribution of these materials in North and South America, enabling Formerra to now support customers who need the same product in all regions.Following GEON's January 2025 acquisition of Foster, the agreement builds on Formerra's long-standing, global partnership with GEON for flexible and rigid PVC and filled polypropylene materials."Bringing Foster's medical-grade portfolio to Europe strengthens our ability to support healthcare manufacturers across the region with specialized compounds and the local expertise they need to navigate complex regulatory environments," said Kelly Wessner, Vice President, Key Accounts, Formerra. "Building on the momentum of our Americas partnership, we're excited to extend these proven solutions to European customers who demand the highest standards in medical device materials."With more than 30 years in custom medical polymer compounding, Foster delivers highly engineered, top-of-the-polymer-pyramid formulations tailored to demanding requirements. The portfolio includes options such as radiopaque compounds and grades that meet USP Class VI requirements and align with ISO 10993 expectations. These materials support critical end uses across the healthcare space, including implantable products and other highly specialized applications."Extending our Foster portfolio into Europe with Formerra allows us to meet growing demand from healthcare manufacturers in one of the world's most dynamic medical device markets," said Arthur Adams, Chief Commercial Officer, GEON. "This expansion reinforces our shared commitment to supporting innovation in life-saving applications globally."Adding Foster® compounds to its European portfolio will enable Formerra to better serve customers in the healthcare space, offering not only access to highly engineered medical polymers, but also deep regulatory expertise and responsive logistics across the region.Formerra will exhibit at MD&M West in Booth 2266 in Anaheim, California, February 3-5, 2026.Key DetailsFormerra will distribute Foster® medical compounds in Europe.This agreement adds custom medical-grade compounds to Formerra's existing global access to GEON® PVC and filled PP materials.About FormerraFormerra is a preeminent distributor of engineered materials, connecting the world's leading polymer producers with thousands of OEMs and brand owners across healthcare, consumer, industrial, and mobility markets. Powered by technical and commercial expertise, it brings a distinctive combination of portfolio depth, supply chain strength, industry knowledge, service, leading e-commerce capabilities, and ingenuity. The experienced Formerra team helps customers across multiple industries to design, select, process, and develop products in new and better ways - driving improved performance, productivity, reliability, and sustainability. To learn more, visit www.formerra.com.About GEON Performance SolutionsGEON® Performance Solutions unlocks the power of polymers for the future. From biomedical materials from our medical division, Foster, LLC, to building materials, automotive, connectivity, and appliances, customers in these markets rely on the portfolio of compounding solutions, highly adaptable vinyl, polyolefin, engineered resin technologies, and full-service contract manufacturing that we deliver. In every formulation, collaboration, and challenge we're shaping the brilliance of tomorrow and providing a formidable advantage by engineering what's possible. Geon has approximately 1,200 global associates and 15 world-class manufacturing plants with headquarters in Westlake, Ohio. Learn more at www.geon.com. Geon is a portfolio company of SK Capital Partners.Media ContactJackie MorrisMarketing Communications Manager, Formerrajackie.morris@formerra.com+1 630-972-3144SOURCE: Formerra Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
HONG KONG, January 30, 2026 - (ACN Newswire via SeaPRwire.com) – A growing number of robotics and artificial intelligence companies backed by Shoucheng Holdings Limited are set to appear at China’s 2026 CMG New Year’s Gala, reflecting the investor’s expanding footprint across the country’s emerging automation and embodied intelligence sectors.The latest company to confirm its participation is Noetix Robotics, according to recent announcements. Shoucheng Holdings led the company’s financing round in 2024 and has continued to increase its investment through subsequent rounds, making it Noetix Robotics’ largest external investor, people familiar with the matter said.Noetix Robotics’ appearance adds to a lineup that already includes other Shoucheng-backed firms. Unitree Robotics, known for its quadruped and humanoid robots, was earlier named a robot partner of the 2026 Gala, marking its third appearance on the program. Beijing Galbot Co., Ltd., which focuses on embodied artificial intelligence systems, has also been designated by China Media Group as the Gala’s embodied large-model robot.The clustering of multiple portfolio companies on the same edition of the Gala places Shoucheng Holdings among a small group of investors with broad representation on one of China’s most-watched annual broadcasts. The event, which regularly draws hundreds of millions of viewers, has increasingly been used as a platform to highlight advances in artificial intelligence, robotics and advanced manufacturing.China Media Group, the organizer of the Gala, has in recent years expanded the role of technology-focused programming, aligning with national policy priorities around intelligent manufacturing and industrial upgrading. While participation in the Gala does not directly translate into revenue, companies and investors see it as an important signal of technical maturity and policy relevance.Unitree Robotics’ repeated appearances underscore this dynamic. The company has previously used the Gala to demonstrate improvements in motion control, balance and coordination, capabilities that are critical as robots move from laboratory environments into commercial and industrial settings. Its continued inclusion suggests confidence in its engineering progress and deployment readiness.Galbot’s designation as the Gala’s embodied large-model robot reflects a broader shift in focus from mechanical performance alone to systems that integrate perception, reasoning and physical execution. Embodied artificial intelligence—where large models are combined with real-world robotic interaction—has become a priority area for Chinese research institutions and technology companies as generative AI expands beyond software applications.The addition of Noetix Robotics introduces another layer to the lineup. The company concentrates on robotic power systems and core engineering components, segments that are increasingly viewed as strategic as China seeks to reduce reliance on imported technologies and strengthen domestic supply chains. Shoucheng Holdings’ sustained backing of Noetix Robotics highlights an investment strategy that spans both complete robotic systems and foundational hardware.Shoucheng Holdings has steadily increased its exposure to robotics over the past several years, backing companies involved in full-stack robotics, embodied intelligence and critical components. Rather than focusing on a single technological approach, the firm has adopted a portfolio strategy that combines capital investment with access to application scenarios and commercialization platforms.One such platform is the Shoucheng Robot Tech Experience Store, a robotics-focused retail and demonstration network operated by the company. While not all Gala participants are Shoucheng investees, some companies, including MagicLab Robotics Technology (Wuxi) Co., Ltd., have placed products such as robotic dogs within the platform’s offline spaces for demonstrations and user engagement. MagicLab was named a strategic intelligent robotics partner for the Year of the Horse CMG New Year’s Gala earlier this year.By linking high-profile media exposure with physical demonstration and sales environments, Shoucheng Holdings aims to accelerate the transition from technology showcase to market adoption, according to people familiar with the platform’s positioning. The approach mirrors a broader trend among Chinese industrial investors to combine financial backing with scenario-based deployment.Industry analysts say the concentration of Shoucheng-backed companies on the 2026 Gala stage illustrates how China’s robotics sector is evolving from isolated prototypes toward more integrated industrial ecosystems. The presence of companies spanning full robotic platforms, embodied intelligence and core engineering components suggests increasing specialization and coordination across the value chain.As preparations for the 2026 CMG New Year’s Gala continue, robotics and artificial intelligence are expected to remain central themes. For Shoucheng Holdings, the event offers a snapshot of how its investments are converging on a national platform, reflecting a strategy that has shifted from selective bets to a broader, system-oriented approach to industrial technology.While the commercial impact of Gala exposure is difficult to quantify, market participants increasingly view the lineup as an indicator of which technologies and companies are gaining momentum within China’s rapidly changing AI and automation landscape. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
HONG KONG, January 30, 2026 - (ACN Newswire via SeaPRwire.com) – Quam Plus International Financial Limited ("Quam Plus Financial" or the "Group") is delighted to announce the successful conclusion of the "3rd Hong Kong Capital Markets Forum 2026" held at the Grand Hyatt Hong Kong. The Group is honored to be one of the Gold Sponsors of this prestigious event. Dr. Kenneth Lam, CEO of the Group, who also serves as Chairman of the Forum Organizing Committee cum Executive Deputy Chairman of The Chamber of Hong Kong Listed Companies (CHKLC), led a delegation of senior management to attend the forum. Mr. Paul Chan Mo-Po, GBM, GBS, MH, JP, Financial Secretary of the Government of HKSAR were also in attendance. Together with prominent figures from the capital markets, government, academia, and the financial sector, they engaged in in-depth discussions on further strengthening Hong Kong's economic momentum.The forum was jointly organized by Hong Kong Association of Registered Public Interest Entity Auditors Limited (PIEAA), The Chamber of Hong Kong Listed Companies (CHKLC), The Hong Kong Institute of Directors (HKIoD), and the Association of Hong Kong Capital Market Practitioners Limited (HKCMP), with strong support from key institutions including Hong Kong Exchanges and Clearing Limited (HKEX), the Securities and Futures Commission (SFC), and the Accounting and Financial Reporting Council (AFRC).As the global economy enters a new cycle of innovation and transformation, this year's forum, themed "Capturing the Next Growth Momentum” explored how Hong Kong can reinvent itself amid a rapidly changing international financial landscape, rebuild confidence, and transform challenges into powerful drivers of progress.As the globalMr. Paul Chan Mo-Po, GBM, GBS, MH, JP, served as the Guest of Honour and delivered the keynote address. He stated: "In my view, the global environment is shifting in ways that create new and favourable opportunities for Hong Kong. Our challenge is how to seize the moment and deliver tangible outcomes. More specifically, that involves supporting the country's high-quality development; matching the needs of Mainland enterprises going global and the appetite of international investors; and, at the same time, driving Hong Kong's own growth."Dr. Kenneth Lam, in his capacity as Chairman of the Forum Organizing Committee, delivered the opening remarks: "As a vital financial hub connecting China and the world, our mission is to strengthen confidence, deepen integration, and expand diverse growth engines. We must keenly identify the next wave of growth drivers and ensure that markets advance in a balanced manner between flexibility and integrity. Positioned at the core of global transformation, this forum reminds us once again that progress is never accidental—it stems from resolute choices: with innovation as our aspiration, collaboration as our bridge, and conviction as our strength, we can lead Hong Kong forward and open up new chapters."Hong Kong now stands at the heart of global change. Advancing the capital markets requires not only visionary policies and regulation but also active participation and collaboration from all sectors. This year's forum focused on two key themes—digital asset development and capital market structural reform—examining how technological innovation can coexist with trust to drive reforms that build greater market resilience.As a proud Gold Sponsor of this year's forum, Quam Plus Financial looks forward to working hand in hand with all stakeholders, including central government offices in Hong Kong and other parties, to propel Hong Kong and the region toward new achievements. Together, we aim to seize new opportunities, activate new momentum, and march toward a high-quality, sustainable financial future.About Quam Plus International Financial LimitedQuam Plus International Financial Limited (the “Company”, Stock Code: 00952.HK) is a Hong Kong based financial services group which is listed on the Main Board of the Stock Exchange of Hong Kong Limited. The Company was publicly listed in Hong Kong in 1997, it is committed to building a comprehensive, full-licensed integrated financial platform. The core businesses of the Company are brokerage business, interest income business, corporate finance business, asset management business and investments and other businesses. The Company strives to become the ideal partner for both corporate and individual investors in Hong Kong and China. The Company also offers premier one-stop financial services to its clients. The Company continued to provide capital markets services through its representative office or the wholly-owned foreign enterprise in Shenzhen, Shanghai, Shenyang, Ningbo, Beijing, Chengdu, Hangzhou and Xiamen of the PRC and through its networks of Global Alliance Partners network and Oaklins International.For further information, please contact:Quam IR LimitedMandy Lo Tel: (852) 2217-2753 Email: mandy.lo@quamgroup.comCharlie Chan Tel: (852) 2217-2504 Email: charlie.chan@quamgroup.com Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
NEEDHAM, MASS., Jan 29, 2026 - (ACN Newswire via SeaPRwire.com) — Bioxytran, Inc. (OTCQB: BIXT) (“Bioxytran” or the “Company”), a clinical-stage biotechnology company developing platform technologies spanning glycovirology, hypoxia, and degenerative diseases, today issued a corporate update summarizing previously disclosed program developments and reinforcing the Company’s strategic direction entering 2026. (BioXyTran)Corporate Update Highlights (Previously Disclosed)ProLectin‑M (broad-spectrum antiviral platform)Bioxytran’s lead antiviral program, ProLectin‑M, is being developed under an active U.S. FDA Investigational New Drug (IND) framework, as previously announced by the Company. In October 2025, the Company announced the completion of a randomized, double-blind, placebo-controlled clinical trial for ProLectin‑M and stated that data from the trial is expected to help inform Phase 3 trial design and be submitted to regulators pursuant to prior regulatory interactions. (BioXyTran)In May 2025, Bioxytran also announced completion of dose optimization work intended to support additional clinical trial planning and agency submissions. Oxygen transport platform (stroke and neurodegenerative diseases)Bioxytran continues to advance its oxygen-transport platform, including development efforts related to a universal oxygen carrier (UOC) and associated measurement/analytical approaches previously described by the Company, including use of the MDX Viewer, which the Company has described as an FDA-approved device to measure tissue oxygenation. In July 2024, Bioxytran announced a joint venture with the Heme Foundation to develop a universal oxygen carrier as an alternative to blood transfusions, including public statements regarding a pledged level of support and reported development progress at that time. Oncology research (Galectin Science)In January 2025, the Company announced a cancer-focused preprint exploring galectin‑3 modulation as a potential strategy to improve response to immune checkpoint inhibitors. (Nasdaq)Management Commentary“Bioxytran enters 2026 with real momentum across our platforms,” said David Platt, Ph.D., Chief Executive Officer of Bioxytran. “Across virology and oxygen transport, our team has stayed focused on disciplined execution—building the data package, advancing the regulatory pathway, and expanding the scientific foundation that supports our programs. We believe our carbohydrate-based approach and galectin science position Bioxytran to pursue meaningful clinical and strategic opportunities as we continue to move forward.” Disclosure NoteThis release is intended as a general corporate update and summarizes information that has been previously disclosed in Company press releases and public filings.About Bioxytran, Inc.Bioxytran is a clinical-stage pharmaceutical company developing platform technologies in glycovirology, hypoxia and degenerative diseases using carbohydrate drug design, including programs that leverage galectin inhibition and programs that aim to address hypoxic conditions and tissue oxygenation. Bioxytran’s common stock trades on the OTCQB under the symbol BIXT.Company Contact:Bioxytran, Inc.75 Second Avenue, Ste 605, Needham, MA 02494Phone: 617‑454‑1199Email: info@bioxytraninc.com Web: www.bioxytraninc.com Forward-Looking StatementsThis press release contains forward-looking statements, including statements regarding anticipated regulatory interactions, future clinical trials, trial designs, timing of data submission and publication, and potential therapeutic and commercial opportunities. Forward-looking statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially. Readers are urged to review the Company’s risk factors disclosed in its reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10‑K for the year ended December 31, 2024. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
SINGAPORE, Jan 29, 2026 - (ACN Newswire via SeaPRwire.com) - LEGENDARY HUMANITY, a Singapore-based company listed on Gate.io, has announced the launch of the "$VIVI RWA MARKET," a new Real World Asset (RWA) marketplace enabling the purchase of exhibited works by contemporary artist Mago Nagasaka. Developed in collaboration with the MAGO Moon Museum, this launch marks a significant milestone in LEGENDARY HUMANITY's ongoing efforts to bridge cultural value and digital infrastructure through real-world assetization.Digitalizing Humanity's Masterpieces Through AI 3D Scanning Technology - A New Purchasing Experience Led by LEGENDARY HUMANITYLEGENDARY HUMANITY PTE. LTD. (Headquarters: Singapore; CEO: Takamasa Suzuki) has officially opened the "$VIVI RWA MARKET," an RWA marketplace where visitors can directly purchase artworks exhibited in the online museum "MAGO Moon Museum," created by contemporary artist Shingo Nagasaka.This initiative forms part of the "VIVI PROJECT," which aims to digitize humanity's masterpieces into digital assets through high-precision, non-contact AI-integrated 3D scanning technology.Through this platform, visitors are able to acquire artworks they have viewed within MAGO Moon Museum as RWAs, enabling a deeper engagement with the artist's worldview and creative philosophy.OverviewName: $VIVI RWA MARKETOpening Date: Thursday, January 29, 2026URL: https://mondo.lhvivi.io/ About "$VIVI RWA MARKET"The "$VIVI RWA MARKET" is an RWA marketplace dedicated to the acquisition of artworks and is embedded within the online museum MAGO Moon Museum.Seamless Pathway from Viewing to PurchaseUsers can seamlessly transition from an artwork's exhibition page to its corresponding RWA product page, creating a unified experience from online viewing to ownership.Integration of Physical and Digital Asset DesignEach artwork includes the following structured information:Physical artwork details (size, materials, condition, provenance)High-resolution digital data generated through AI 3D scanningArtist profile and project background informationalong with other curated metadata.This structure allows users to acquire artworks with a proper understanding of their cultural and artistic value.Ecosystem Holding FunctionalityAcquired works will gradually gain viewing and management functionality within the VIVI ecosystem. While future integration with VIVI COiN is under consideration, the current initiative is focused solely on enhancing the preservation, appreciation, and understanding of the artworks.About LEGENDARY HUMANITY and the VIVI PROJECTLEGENDARY HUMANITY promotes the "VIVI PROJECT," which digitizes legendary masterpieces created by humanity into digital assets using high-precision, non-contact, AI-integrated 3D scanning technology. The project operates under the vision of "Bringing the beauty of humanity to AI and the future."Targeted assets include:Legendary fashion collectionsHistorical architecture and cultural masterpiecesFamous trading cardsArtworks, including those exhibited at MAGO Moon Museumand other assets that can be described as humanity's masterpieces.The VIVI PROJECT aims to:Digitize assets as digital cultural heritageTokenize them as RWAs for global circulationExhibit them in both online and physical museumsthereby building new infrastructure that harmonizes cultural and economic value.NEXT SOCIETY (Gacha Location): https://nextsociety.lhvivi.ioRWA Market RoadmapThe launch of the "$VIVI RWA MARKET" represents the first phase of RWA market functionality within the VIVI PROJECT. Planned future developments include:VIVI FASHION (RWA for the fashion domain)VIVI TRADING CARD (RWA for the trading card domain)VIVI ART WORK (RWA for art collections)with future integration under consideration.About MAGO Moon MuseumMAGO Moon Museum is an online museum created by contemporary artist Shingo Nagasaka, whose works explore themes related to electronic waste issues in Agbogbloshie, Ghana.The museum provides an online space to view Nagasaka's representative works, including pieces created from discarded electronic components found in Ghanaian slums, as well as series examining the concept of "Sustainable Capitalism."With the implementation of the "$VIVI RWA MARKET," viewers can deepen their understanding of the artworks while acquiring pieces aligned with the artist's philosophy in an appropriate and structured manner.Future DevelopmentsBuilding on this initiative, LEGENDARY HUMANITY plans to:Expand collaborations with masterpieces across different regions and genresStrengthen international networks with artists, collectors, and researchersAdvance technological development for the preservation of cultural assets for future generationsand continue developing as a platform that passes humanity's masterpieces into the future through real-world assets.Media ContactCompany Name: LEGENDARY HUMANITY PTE. LTD.Address: 105 Cecil St, The Octagon 24F-2, Singapore 06953Representative: Takamasa Suzuki, LEGENDARY HUMANITY / VIVI PROJECT Public Relations DeskEmail: info@lhvivi.com Related URL: $VIVI RWA MARKET https://mondo.lhvivi.io Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
香港, 2026年1月29日 - (亚太商讯 via SeaPRwire.com) - 2026年的中国生猪养殖业，正站在一个结构性变革的关键节点。2025年，反内卷产能调控政策成为生猪市场的核心影响变量，政策持续引导产能有序退出，稳价成为主旋律。市场普遍预期，在调控深化与产能去化的共同作用下，2026年猪价大概率将呈现「前低后高」的走势，行业有望在中期迎来周期性向上拐点，并步入全新的发展阶段。在此背景下，中国生猪养殖龙头牧原食品股份有限公司（下称「牧原股份」或「公司、股份代号：02714.HK）赴港上市，于1月29日开启招股，全球发售273,951,400股，最高发售价为39.00港元，预计于2026年2月6日上市。作为全球最大的生猪养殖企业，牧原股份凭借深耕三十余年的全产业链积淀、领先的科技实力与稳健的盈利表现，充分彰显智慧生猪养殖行业领航者的硬核竞争力。全产业链赋能 盈利韧性领跑行业作为智慧生猪养殖的领航者，牧原股份深耕中国生猪养殖行业30余年，构建了覆盖生猪育种、养殖、饲料生产、屠宰肉食的垂直一体化商业模式，实现了上下游环节的高效协同与标准化管理，建立起全流程可知可控可追溯、精细化成本控制的运营体系，凭借这一模式与核心技术、成本管理能力，达成了规模、增长与盈利的三重平衡。据弗若斯特沙利文统计，自2021年起，牧原股份生猪产能及出栏量连续四年位居全球第一，2024年全球市场份额攀升至5.6%，超过第二至第四位参与者合计份额；屠宰肉食业务同样表现亮眼，2024年按屠宰头数计位列全球第五、中国第一，2021至2024年收入复合增速领跑国内同行。牧原股份坚持科技立业，作为智慧生猪养殖领航者，在生物安全、臭气治理、环境运营及成本管控领域持续叠代技术、突破行业痛点，提升效率、降低成本并创造社会价值。多年深耕下，公司不仅稳固行业领先地位，更实现优异盈利：2014-2024年，总收入、凈利润复合年均增长率分别达48.7%、72.7%，平均凈利润率19.0%，是全球十大猪肉食品上市企业中唯一同期超15%的企业；同期EBITDA复合增速60.2%，利润率30.8%，优于国内同行。全球化布局技术出海 行业前景广阔国际化是牧原股份核心发展战略之一，公司正将国内成熟的技术与成本优势复制至海外高潜力市场。目前，牧原股份以技术输出为先导，在东南亚市场布局成效显著：2024年9月，与越南BAF公司达成战略合作，提供全流程养殖服务，迈出全球化第一步；2025年8月，与正大集团签署协议，围绕多领域深化协同，借助其渠道影响力开拓全球市场；2025年9月，与BAF公司进一步合作，计划在越南西宁省建设高科技楼房养殖及配套饲料厂，总投资32亿元，达产后年供商品猪160万头，集中展现国内前沿养殖模式与成本控制能力。从行业前景看，全球生猪养殖行业蕴藏的重大发展机遇。据弗若斯特沙利文统计，全球猪肉消费量稳步攀升，2020年至2024年从9520万吨增长至11530万吨，复合年均增长率达4.9%。作为全球第一大猪肉消费国，中国市场增长潜力依然可观，2024年人均主要肉类消费量为69.4公斤/人，相较于美国的102.0公斤/人仍有显著提升空间。除中国市场外，东南亚地区已成为猪市增长新引擎，随着当地经济持续发展、人均收入不断提升，越南、泰国、菲律宾等国人均猪肉消费量逐步增长，形成了极具潜力的海外增量市场为牧原股份全球化布局提供广阔展空间。牧原股份凭借港股上市的资本助力、全产业链的核心壁垒、技术输出的先发优势，有望在全球市场竞争中持续领跑。未来，牧原股份将以「A+H」双平台为支撑，将成熟的运营模式与技术经验辐射至更多海外市场，深耕产业互联、推动合作创新，践行联农助农理念、实现双向共赢发展，为广大投资者带来长期稳定的回报。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
HONG KONG, January 29, 2026 - (ACN Newswire via SeaPRwire.com) – Standard Chartered and the Hong Kong Trade Development Council (HKTDC) have jointly released the latest Standard Chartered Greater Bay Area Business Confidence Index (GBAI), which revealed that the business sentiment for most companies in the Greater Bay Area (GBA) remained steady amid persistent external uncertainties in Q4-2025. The GBA Index is released quarterly in January, April, July, and October each year.Following a rebound in the previous quarter, the GBAI indices showed a moderate quarter-on-quarter retreat in the fourth quarter of 2025. This has been seen as the result of diminishing returns from front-loading activities and from a more cautious approach to investment, financing, and capacity utilisation amid ongoing external uncertainties.The “current performance” index for business activity in Q4 retreated to 50.3 from 54.7 in the previous quarter, while the “expectations” index dropped to 51 from 55.7. Despite the drop, both indices remained in expansionary territory, indicating that GBA businesses still maintained a broadly positive outlook.Turning to the sub-indices, a mixed picture emerged for both “current performance” and “expectations” for the quarter overall. More specifically, with regard to “current performance”, the “new orders”, “fixed asset investment” and “profit” sub-indices all fell below the 50 watershed level. This, however, was seen as a correction following the end of the front-loading process in earlier quarters. Subdued growth in loans and fixed-asset investment in the Chinese Mainland also contributed to this slight downward trend.On the contrary, the “expectations” remained relatively positive, with sub-indices for “production/sales”, “new orders” and “profits” all staying in expansionary territory in the fourth quarter last year. Taken together, these upbeat outcomes suggest a strong likelihood that robust demand will persist through the first quarter of 2026 and beyond.In terms of individual GBA city evaluations, Hong Kong's readings were well above the survey average. This confirmed that the city’s economic rebound remained on course at year-end, with the “current performance” sub-index up 5.7 points to 57.9 and the “expectations” reading up 1.8 points to 55.4. Overall, this sustained recovery in growth momentum was attributed to the city’s “professional services” and “retail/wholesale” sectors.Wing Chu, Deputy Director of Research, HKTDC, said: “Following the extension of the trade truce between the US and China, business sentiment in Hong Kong continued to improve, allowing the city to outperform its peer cities across the GBA. This strength stands in contrast to the broader moderation seen in the overall GBA indices amid persistent external uncertainties. This momentum in Hong Kong's recovery is expected to remain intact, supported by buoyant business activity and the professional services sector's solid performance– key factors that underscore the city’s recovery trajectory. The HKTDC will continue to proactively support GBA enterprises in leveraging Hong Kong's professional services to ‘go global’ and capitalise on opportunities in emerging markets, including those in the Middle East.”In order to get a greater understanding of the wider aspirations of GBA businesses, the survey also examined their interest in the expansion into the Middle East. Encouragingly, over half of respondents (54.8%) expressed interest in expanding into the Middle East, with the UAE (53.9%) and Saudi Arabia (53.2%) selected as the top two priority markets.Digging deeper into these findings, of the companies that have already started or are interested in expanding into the Middle East, nearly 60% were engaged in trading/ distribution activity. This was followed by manufacturing (42.7%) and logistics/ storage (28.3%).Despite widespread optimism about emerging opportunities in the Middle East, many GBA businesses were also aware they faced several challenges in ensuring success. Overall, the top three concerns here were: “lack of understanding of local laws and regulations” (50.4%), “opaque local regulatory environment and restrictions on foreign investment” (43.1%) and “cultural and business differences” (42%).Crucially, to help manage such challenges, 99.2% of respondents saw Hong Kong’s world-class services as pivotal to the success of their Middle East expansion plans. Particular emphasis was placed on the decisive contribution of the city’s professional services sector, especially in successfully navigating local regulatory and compliance requirements.Hunter Chan, Economist, Greater China, Standard Chartered, said: “With increasingly complex geopolitical risks, global corporates not only actively diversify their supply chains but also explore new markets in recent years, thereby giving rise to numerous emerging trade corridors. The thematic survey found that the GBA corporates are interested in entering the Middle East, which aligns with Hong Kong Government’s policy focus to set up the ‘GoGlobal Task Force’ to leverage Hong Kong’s advantages as a ‘go global’ platform, and deepen economic ties with the Middle East. The survey also found that almost all respondents indicate that Hong Kong services are needed to help in expansion into the Middle East to address the challenges posed by local regulations and cultural differences. With its advantage in professional services, Hong Kong can further leverage its unique position as a ‘super-connector’, becoming a springboard for enterprises to develop overseas markets.”About the GBAIThe Standard Chartered Greater Bay Area Business Confidence Index (GBAI), jointly presented by Standard Chartered and Hong Kong Trade Development Council, is the first forward-looking quarterly survey in the market that examines business sentiment and synergistic effects in the Guangdong-Hong Kong-Macao Greater Bay Area ("Greater Bay Area" or "GBA"). The index is computed from the analysis of more than 1,000 responses from GBA companies regarding their overall operations, business environment, and expansion plans. The index includes five sub-indices that indicate business confidence for each industry, including manufacturing & trading, retail & wholesale, financial services, professional services, and innovation & technology. It enables investors and businesses to better understand the current business climate, gauge future performance and formulate their market strategies in the Greater Bay Area. Related materialsStandard Chartered GBA Business Confidence Index Report:https://www.sc.com/hk/gba/gba-index-report/HKTDC Research: https://research.hktdc.com/en/article/MjIzMTk3MzQwOAMedia enquiriesStandard Chartered Bank (Hong Kong) Limited, Corporate Affairs DepartmentFlora Chiu, Tel: +852 3843 2285, Email: flora.chiu@sc.com HKTDC Communications & Public Affairs Department:Katy Wong, Tel: +852 2584 4524, Email: katy.ky.wong@hktdc.orgClayton Lauw, Tel: +852 2584 4472, Email: clayton.y.lauw@hktdc.orgAbout Standard CharteredWe are a leading international banking group, with a presence in 54 of the world’s most dynamic markets. Our purpose is to drive commerce and prosperity through our unique diversity, and our heritage and values are expressed in our brand promise, here for good.Standard Chartered PLC is listed on the London and Hong Kong stock exchanges.The history of Standard Chartered in Hong Kong dates back to 1859. It is currently one of the Hong Kong SAR’s three note-issuing banks. Standard Chartered incorporated its Hong Kong business on 1 July 2004, and now operates as a licensed bank in Hong Kong under the name of Standard Chartered Bank (Hong Kong) Limited, a wholly owned subsidiary of Standard Chartered PLC.For more stories and expert opinions, please visit Insights at sc.com. Follow Standard Chartered on X, LinkedIn, Instagram and Facebook.About HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
HONG KONG, January 29, 2026 - (ACN Newswire via SeaPRwire.com) – Quam Plus International Financial Limited ("Quam Plus Financial" or the "Group") is delighted to announce the successful conclusion of the "3rd Hong Kong Capital Markets Forum 2026" held at the Grand Hyatt Hong Kong. The Group is honored to be one of the Gold Sponsors of this prestigious event. Dr. Kenneth Lam, CEO of the Group, who also serves as Chairman of the Forum Organizing Committee cum Executive Deputy Chairman of The Chamber of Hong Kong Listed Companies (CHKLC), led a delegation of senior management to attend the forum. Mr. Xu Weigang, Director-General of the Economic Affairs Department of the Liaison Office of the Central People's Government in the HKSAR, and Mr. Paul Chan Mo-Po, GBM, GBS, MH, JP, Financial Secretary of the Government of HKSAR were also in attendance. Together with prominent figures from the capital markets, government, academia, and the financial sector, they engaged in in-depth discussions on further strengthening Hong Kong's economic momentum.The forum was jointly organized by Hong Kong Association of Registered Public Interest Entity Auditors Limited (PIEAA), The Chamber of Hong Kong Listed Companies (CHKLC), The Hong Kong Institute of Directors (HKIoD), and the Association of Hong Kong Capital Market Practitioners Limited (HKCMP), with strong support from key institutions including Hong Kong Exchanges and Clearing Limited (HKEX), the Securities and Futures Commission (SFC), and the Accounting and Financial Reporting Council (AFRC).As the global economy enters a new cycle of innovation and transformation, this year's forum, themed "Capturing the Next Growth Momentum” explored how Hong Kong can reinvent itself amid a rapidly changing international financial landscape, rebuild confidence, and transform challenges into powerful drivers of progress.Mr. Paul Chan Mo-Po, GBM, GBS, MH, JP, served as the Guest of Honour and delivered the keynote address. He stated: "In my view, the global environment is shifting in ways that create new and favourable opportunities for Hong Kong. Our challenge is how to seize the moment and deliver tangible outcomes. More specifically, that involves supporting the country's high-quality development; matching the needs of Mainland enterprises going global and the appetite of international investors; and, at the same time, driving Hong Kong's own growth."Dr. Kenneth Lam, in his capacity as Chairman of the Forum Organizing Committee, delivered the opening remarks: "As a vital financial hub connecting China and the world, our mission is to strengthen confidence, deepen integration, and expand diverse growth engines. We must keenly identify the next wave of growth drivers and ensure that markets advance in a balanced manner between flexibility and integrity. Positioned at the core of global transformation, this forum reminds us once again that progress is never accidental—it stems from resolute choices: with innovation as our aspiration, collaboration as our bridge, and conviction as our strength, we can lead Hong Kong forward and open up new chapters."Hong Kong now stands at the heart of global change. Advancing the capital markets requires not only visionary policies and regulation but also active participation and collaboration from all sectors. This year's forum focused on two key themes—digital asset development and capital market structural reform—examining how technological innovation can coexist with trust to drive reforms that build greater market resilience.As a proud Gold Sponsor of this year's forum, Quam Plus Financial looks forward to working hand in hand with all stakeholders, including central government offices in Hong Kong and other parties, to propel Hong Kong and the region toward new achievements. Together, we aim to seize new opportunities, activate new momentum, and march toward a high-quality, sustainable financial future.About Quam Plus International Financial LimitedQuam Plus International Financial Limited (Stock Code: 00952.HK) is a Hong Kong based financial services group which is listed on the Main Board of the Stock Exchange of Hong Kong Limited. The Company was publicly listed in Hong Kong in 1997, it is committed to building a comprehensive, full-licensed integrated financial platform. The core businesses of the Company are brokerage business, interest income business, corporate finance business, asset management business and investments and other businesses. The Company strives to become the ideal partner for both corporate and individual investors in Hong Kong and China. The Company also offers premier one-stop financial services to its clients. The Company continued to provide capital markets services through its representative office or the wholly-owned foreign enterprise in Shenzhen, Shanghai, Shenyang, Ningbo, Beijing, Chengdu, Hangzhou and Xiamen, PRC and through its Global Alliance Partners network and Oaklins International. Visit https://www.quamplus.com/en.For further information, please contact:Quam IR LimitedMandy Lo, Tel: (852) 2217-2753, Email: mandy.lo@quamgroup.comCharlie Chan, Tel: (852) 2217-2504, Email: charlie.chan@quamgroup.com Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
